Study of a Novel Antipsychotic ITI-007 in Schizophrenia

Schizophrenia Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01499563
• Other study ID #: ITI-007-005
• Status: Completed
• Phase: Phase 2
• First received: December 16, 2011
• Last updated: March 9, 2017
• Start date: December 2011
• Est. completion date: November 2013

Study information

• Verified date: September 2014
• Source: Intra-Cellular Therapies, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms associated with schizophrenia in patients who are having an acute worsening of their psychosis. Patients will be randomly assigned to receive one of two doses of ITI-007, placebo, or a positive control. The primary goal will be to assess the effects of ITI-007 on psychosis. The safety of ITI-007 will also be assessed.

Description:

The study will be conducted as a randomized, double-blind, placebo-controlled, multi-center study in patients diagnosed with schizophrenia and an acute exacerbation of psychosis. The efficacy and safety of two dose levels of ITI-007 administered daily for 28 days will be evaluated as compared to placebo; risperidone has been included as a positive control.

Upon completion of the inpatient 28-day Study Treatment Period, patients will be started on standard antipsychotic medication and will be stabilized over a 5-day period before discharge from the study clinic. Patients will be seen for a final outpatient safety evaluation at the End-of-Study visit approximately 2 weeks after discharge.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 335
• Est. completion date: November 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Patient's age is 18-55

• Patient has current diagnosis of schizophrenia and is experiencing an acute exacerbation of psychosis

• Patient has a history of at least three months exposure to one or more antipsychotic therapy(ies) and a prior response to antipsychotic therapy within the previous five years

Exclusion Criteria:

• Any female patient who is pregnant or breast-feeding

• Any patient presenting with concurrent dementia, delirium, mental retardation, epilepsy, drug-induced psychosis, or history of significant brain trauma

• Any patient presenting with schizoaffective disorder, bipolar disorder, acute mania, or major depression with psychotic features

• Any patient considered to be an imminent danger to themselves or others

• Any patient with hematological, renal, hepatic, endocrinological, neurological, or cardiovascular disease or substance abuse as defined by protocol

• Any patient judged by the Investigator to be inappropriate for the study

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• ITI-007
Capsules containing ITI-007 for 28 days
• Placebo
Capsules containing inactive placebo for 28 days
• Risperidone
Capsules containing risperidone for 28 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Intra-Cellular Therapies, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positive and Negative Syndrome Scale (PANSS) total score		Change from baseline to Day 28
Secondary	Positive and Negative Syndrome Scale (PANSS) total score		Change from baseline to Day 8, 15, 22